s6y

MAIA Biotechnology, Inc.

Ticker
MAIA
CIK
1878313
Industry
Pharmaceutical Preparations

Financials 19

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 19 financials filings

News 111

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 111 news filings

Ownership 257

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 257 ownership filings

Prospectus 52

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. S-3 Registration statement for specified transactions by certain issuers
  4. S-3 Registration statement for specified transactions by certain issuers
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  10. 424B5 Prospectus filed pursuant to Rule 424(b)(5)

All 52 prospectus filings

Proxies 9

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  8. DEF 14A Definitive proxy statements
  9. DEF 14A Definitive proxy statements

Other 59

  1. EFFECT Notice of Effectiveness
  2. EFFECT Notice of Effectiveness
  3. SCHEDULE 13G/A
  4. SCHEDULE 13G
  5. ARS Annual report to security holders
  6. D Exempt (Private) Offering
  7. SCHEDULE 13D/A
  8. D Exempt (Private) Offering
  9. D Exempt (Private) Offering
  10. D Exempt (Private) Offering

All 59 other filings